ER and PR expression and survival after endometrial cancer

Smith, Deborah S.; Stewart, Colin J.R.; Clarke, Edward M.; Lose, Felicity; Davies, Claire; Armes, Jane E.; Obermair, Andreas; Brennan, Donal J.; Webb, Penelope M.; Nagle, Christina M.; Spurdle, Amanda B.

doi:10.1016/j.ygyno.2017.11.027

Cited by 52 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, patients with type I endometrial cancer are frequently afflicted with hyperestrogenism, hyperlipidemia, diabetes, and anovulatory uterine bleeding; all of these conditions are associated with the metabolic syndrome, which has been identified as an independent risk factor for the development of endometrial cancer . Histologically, type I tumors are predominantly well‐differentiated to moderately differentiated endometrioid tumors, and at least 90% express moderate to high levels of the estrogen receptor . Type II endometrial cancers, in contrast, are not associated with hyperestrogenemia or endometrial hyperplasia, often arise in nonobese women, and are not associated with metabolic or endocrine disorders.…”

Section: Prognostic Factorsmentioning

confidence: 99%

“…12 Histologically, type I tumors are predominantly welldifferentiated to moderately differentiated endometrioid tumors, and at least 90% express moderate to high levels of the estrogen receptor. 13 Type II endometrial cancers, in contrast, are not associated with hyperestrogenemia or endometrial hyperplasia, often arise in nonobese women, and are not associated with metabolic or endocrine disorders. Histologically, type II tumors are poorly differentiated, most commonly serous, clear cell, or carcinosarcoma subtypes.…”

Section: Prognostic Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Current recommendations and recent progress in endometrial cancer

Brooks

Fleming

Lastra

et al. 2019

CA A Cancer J Clinicians

446

372

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecologic cancer in the United States, and its incidence is rising. Although there have been significant recent advances in our understanding of endometrial cancer biology, many aspects of treatment remain mired in controversy, including the role of surgical lymph node assessment and the selection of patients for adjuvant radiation or chemotherapy. For the subset of women with microsatellite‐instable, metastatic disease, anti– programmed cell death protein 1 immunotherapy (pembrolizumab) is now approved by the US Food and Drug Administration, and numerous trials are attempting to build on this early success.

show abstract

Section: Prognostic Factorsmentioning

confidence: 99%

Section: Prognostic Factorsmentioning

confidence: 99%

Current recommendations and recent progress in endometrial cancer

Brooks

Fleming

Lastra

et al. 2019

CA A Cancer J Clinicians

446

372

View full text Add to dashboard Cite

show abstract

“…Chemotherapy or other treatments stimulate a variety of immunological responses, and this process generates a variety of autoantibodies that might show high binding with 16α‐OHE 1 ‐ERα. ER and PR have been expressed in endometrial tissues, and their expression has been significantly associated with EC 35 . Their status is an independent predictor for EC.…”

Section: Discussionmentioning

confidence: 99%

Endometrial cancer patients have high affinity antibodies for estrogen metabolite–receptor aggregate: A potential biomarker for EC

Khan

Alsamghan

Khan

2020

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim: Elevated levels of 16α-hydroxyestrone (16α-OHE 1) have been described in endometrial cancer (EC) and estrogen receptors (ER) expressed in endometrial tissue, but research on their combined role is lacking. We aimed to investigate the affinity and binding specificity of EC antibodies against the 16α-OHE 1-ERα aggregate in the serum of EC patients. Specificities of EC antibodies were also evaluated according to various clinical characteristics found in these cancer patients. Methods: The binding specificity and affinity of EC antibodies against 16α-OHE 1-ERα in the serum of 120 EC patients were evaluated by direct binding and competition ELISA and quantitative precipitation titration. Binding of EC antibodies was also determined according to various clinical characteristics in EC patients through competition ELISA. Results: Antibodies from EC patients demonstrated high recognition of 16α-OHE 1-ERα compared to ERα (P < 0.05) or 16α-OHE 1 (P < 0.001). The relative affinity of EC IgG was 1.49 × 10 −7 M, 1.34 × 10 −6 M and 1.13 × 10 −6 M for 16α-OHE 1-ERα, ERα and 16α-OHE 1 , respectively. Several factors, such as obesity, postmenopausal status, use of hormonal therapy, ER and progesterone receptor (PR) status, low 2-OHE 1 /16α-OHE 1 ratio, chemotherapy and hypertension, augment the production of antibodies against 16α-OHE 1-ERα in EC patients. Conclusion: 16α-OHE 1-ERα is a high-affinity antigen for EC antibodies in the serum of EC patients and might function as a biomarker for this disease. Furthermore, several factors enhanced the production of antibodies against 16α-OHE 1-ERα in the sera of these EC patients.

show abstract

“…Stage and features of the primary tumor, such as histologic subtype, grade, depth of myometrial invasion, and lymphovascular space invasion, are among the most commonly used prognosticators in clinical practice 13. Many tissue biomarkers (eg, L1CAM)14 15 and estrogen and progesterone receptor status,16 have been proposed as molecular determinants of patient outcome. Of the blood-based assays, CA12517 and HE418 have been suggested to serve as prognostic biomarkers in endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

American Society of Anesthesiologists physical status score as a predictor of long-term outcome in women with endometrial cancer

Kolehmainen¹,

Pasanen

Tuomi

et al. 2019

Int J Gynecol Cancer

View full text Add to dashboard Cite

ObjectiveTo study the association of the American Society of Anesthesiologists (ASA) physical status score with long-term outcome in endometrial cancer.MethodsOverall, disease-specific and non-cancer-related survival were estimated using simple and multivariable Cox regression analyses and the Kaplan-Meier method.ResultsA total of 1166 patients were included in the study. Median follow-up time was 76 (range 1–136) months. All-cause and non-cancer-related mortality were increased in patients whose ASA physical status score was III (HRs 2.5 and 8.0, respectively) or IV (HRs 5.7 and 25, respectively), and cancer-related mortality was increased in patients whose score was IV (HR 2.7). Kaplan-Meier analyses demonstrated a worse overall, disease-specific and non-cancer-related survival for patients whose score was ≥III (p<0.0001 for all). Disease-specific survival was also separately analyzed for patients with stage I and stage II–IV cancer. Compared with patients whose score was ≤II, the survival was worse for patients whose score was ≥III in both subgroups of stages (p=0.003 and p=0.017 for stage I and stages II–IV, respectively). ASA physical status score remained an independent predictor of all-cause mortality (HR 2.2 for scores ≥III), cancer-related mortality (HRs 1.7 and 2.2 for scores ≥III and IV, respectively) and non-cancer related mortality (HR 3.1 for scores ≥III) after adjustment for prognostically relevant clinicopathologic and blood-based covariates. ASA physical status score also remained an independent predictor of cancer-related mortality after exclusion of patients who were at risk for nodal involvement based on features of the primary tumor but who did not undergo lymphadenectomy, and patients with advanced disease who received suboptimal chemotherapy (HRs 1.6 and 2.5 for scores ≥III and IV, respectively).ConclusionsASA physical status score independently predicts overall survival, disease-specific survival, and non-cancer-related survival in endometrial cancer.

show abstract

ER and PR expression and survival after endometrial cancer

Cited by 52 publications

References 31 publications

Current recommendations and recent progress in endometrial cancer

Current recommendations and recent progress in endometrial cancer

Endometrial cancer patients have high affinity antibodies for estrogen metabolite–receptor aggregate: A potential biomarker for EC

American Society of Anesthesiologists physical status score as a predictor of long-term outcome in women with endometrial cancer

Contact Info

Product

Resources

About